Nektar Therapeutics (NASDAQ:NKTR) Stock Gets Downgrade from Wall Street Zen

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other equities research analysts have also issued reports on NKTR. TD Cowen raised shares of Nektar Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. JPMorgan Chase & Co. initiated coverage on shares of Nektar Therapeutics in a report on Friday, August 21st. They set a “neutral” rating and a $65.00 price objective for the company. UBS Group started coverage on shares of Nektar Therapeutics in a report on Monday, October 12th. They set a “neutral” rating and a $53.00 price objective for the company. Raymond James Financial initiated coverage on shares of Nektar Therapeutics in a research report on Friday, October 9th. They set a “market perform” rating on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $178.00 target price on shares of Nektar Therapeutics in a research note on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $130.67.

Check Out Our Latest Stock Analysis on NKTR

Nektar Therapeutics Stock Performance

NKTR opened at $37.27 on Friday. The stock has a market cap of $1.27 billion, a PE ratio of -5.77 and a beta of 1.45. Nektar Therapeutics has a 1 year low of $33.40 and a 1 year high of $109.00. The stock’s 50 day simple moving average is $48.47 and its 200-day simple moving average is $64.54.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating analysts’ consensus estimates of ($2.07) by $0.44. The business had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.27 million. Nektar Therapeutics had a negative return on equity of 29.31% and a negative net margin of 339.67%. Equities analysts forecast that Nektar Therapeutics will post -8.08 earnings per share for the current fiscal year.

Insider Activity at Nektar Therapeutics

In related news, CEO Howard Robin sold 418 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total transaction of $30,087.64. Following the completion of the transaction, the chief executive officer owned 54,627 shares in the company, valued at $3,932,051.46. This trade represents a 0.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is owned by company insiders.

Institutional Trading of Nektar Therapeutics

A number of large investors have recently bought and sold shares of the stock. Orbimed Advisors LLC bought a new stake in shares of Nektar Therapeutics during the first quarter worth $19,786,000. Two Seas Capital LP increased its stake in shares of Nektar Therapeutics by 8.2% in the third quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock valued at $202,582,000 after buying an additional 253,744 shares in the last quarter. Braidwell LP increased its stake in shares of Nektar Therapeutics by 112.7% in the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after buying an additional 250,916 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Nektar Therapeutics in the second quarter valued at $6,706,000. Finally, ACT Capital Partners L.P. acquired a new stake in shares of Nektar Therapeutics in the third quarter valued at $5,473,000. 75.88% of the stock is currently owned by institutional investors.

Trending Headlines about Nektar Therapeutics

Investors following NKTR have been watching these headlines:

  • Positive Sentiment: Nektar’s loss of $1.63 per share was narrower than analysts’ estimates. The company also said it had initiated all three Phase 3 ZENITH trials for rezpegaldesleukin in atopic dermatitis, with an alopecia areata trial planned for December. Zacks Q3 results and outlook
  • Positive Sentiment: The company reported $952.9 million in cash and marketable securities at quarter-end, providing resources to advance its clinical programs. Nektar Q3 financial results
  • Negative Sentiment: Nektar cut its 2026 revenue outlook, a key reason shares were reported down 4.5%. Quarterly revenue of $9.4 million missed the roughly $10.3 million consensus and declined from $11.8 million a year earlier. Zacks Q3 results and outlook

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

Further Reading

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.